

Notice: This is a translation of a notice in Japanese and is made solely for the convenience of foreign shareholders.

In the case of any discrepancy between the translation and the Japanese original, the latter shall prevail.

(Translation)

June 24, 2024

To Shareholders,

Company Name Renaissance Inc.

Representative: Koji Naito, President & CEO

(Code: 4889 TSE Growth)

For inquiries, please contact Administration Dept.

Notice of Conclusion of Collaboration Agreement with Luxna Biotech Co., Ltd.

The Company is pleased to announce that it has decided to enter into the Collaboration Agreement on a novel biopharmaceutical (oligonucleotide therapeutics) with Luxna Biotech Co., Ltd (“Luxna Biotech”).

1. Background of the Collaboration Agreement.

The Company has been conducting research and development of medical solutions utilizing various modalities to solve medical issues, and several pipelines are in the clinical stage utilizing investigator-initiated clinical trials.

Luxna Biotech has been conducting research and development of biopharmaceuticals (oligonucleotide therapeutics) with high efficacy and safety by utilizing the drug discovery technology with artificially modified nucleic acids developed by Professor Satoshi Kobiga of the Graduate School of Pharmaceutical Sciences, Osaka University.

Both companies will jointly conduct research, clinical development, and commercialization of new oligonucleotide therapeutics by utilizing Luxna Biotech's artificial modified nucleic acid technology and the Company's track record and experience in investigator-initiated clinical trials.

2. Details of the Collaboration Agreement

The purpose of the Collaboration Agreement is to jointly develop novel oligonucleotide therapeutics for hereditary neurological and other intractable diseases.

The Company and Luxna Biotech will formulate the development strategy, and will ensure efficient research and development of the products by jointly conducting optimization, manufacturing, non-clinical testing, and clinical trials.

3. Outlook for Future

This matter will have no impact on the forecast of business results for the fiscal year ending March 31, 2025.

<Reference>

[Luxna Biotech Co., Ltd.]

Luxna Biotech is a biotech company established to promote the practical application of safe and effective pharmaceuticals using a drug discovery platform for oligonucleotide therapeutics based on a group of artificially modified nucleic acids originating from Osaka University. With antisense oligo as its main product, Luxna Biotech aims to deliver oligonucleotide therapeutics that can help patients fighting serious illness with no effective medicines and their supporters. For more information, please visit the company's website at <https://luxnabiotech.co.jp/>.

End